Fig. 6: Comparing neutralizing activity against variants across vaccine platforms in neonates of vaccinated patients. | Nature Communications

Fig. 6: Comparing neutralizing activity against variants across vaccine platforms in neonates of vaccinated patients.

From: SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates

Fig. 6

a–c Neutralizing activity against a B.1, b BA.1, and c BA.5 variants in umbilical cord blood from patients with a positive history of SARS-CoV-2 infection compared across vaccine platforms; mRNA1273 (Moderna, purple) and BNT162b2 (Pfizer-BioNTech, orange). Samples are stratified by patient vaccination status at time of delivery; Partially vaccinated with a positive history of infection (PartVx/Inf), Fully vaccinated with a positive history of infection (FullVx/Inf) and Boosted with a positive history of infection (BoostVx/Inf). Data points are indicated as dots and plotted as boxplots (center line, median; bounds of box, the first and third quartiles; whiskers, 1.5 times interquartile range). Significance was determined by two-sided Wilcoxon rank-sum Test. Source data are provided as a source data file.

Back to article page